Peter Strumph

Peter Strumph is a seasoned executive with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as the Chief Executive Officer at Parvus Therapeutics Inc since June 2021, Peter is focused on developing Navacims, a novel platform technology aimed at treating autoimmune diseases. Additionally, Peter holds the title of Chief Executive Officer and Member of the Board of Directors at Amygdala Neurosciences Inc since January 2016. Previous roles include Senior Vice President of Clinical and Technical Operations at Portola Pharmaceuticals, interim Chief Executive Officer and various senior leadership positions at Codexis, Chief Executive Officer at Nile Therapeutics Inc, and Senior Vice President of Operations at CV Therapeutics. Peter began a career with foundational roles at Biogen, Bio-Rad Laboratories, and Bayer, following service as a Lieutenant in the US Navy. Educational credentials include an MBA in Finance and Healthcare from The Wharton School and a BAS in System Science and Engineering from the University of Pennsylvania.